- Develop and implement clinical decision support tools to increase adherence to accepted clinical best practices, improve clinical outcomes and lower hospitalization costs for patients.
- Quantify and reduce the risk and severity of acute pancreatitis due to the procedure endoscopic retrograde cholangio-pancreatography (ERCP) through patient selection, pharmacologic therapy, hydration and prophylactic pancreatic duct stenting.
- Investigate molecular mechanisms of pancreatic injury, healing and/or pancreatic cancer (e.g. ADAM17, Hedgehog signaling) that may translate to future clinical treatment targets
- Measure and identify specific factors that influence quality of life
- Characterize pain pattern and identify predictors for reducing abdominal pain in response to medical, endoscopic and surgical interventions
- Improve the clinical application of endoscopic ultrasonography, direct pancreatic function testing and biomarkers to establishing a firm diagnosis of chronic pancreatitis
- Determine the most effective medical treatment
- Identify prognostic markers to disease progression and risk for cancer
- Determine cancer risk in hereditary pancreatitis and other familial pancreatic cancer conditions
- Develop a patient registry and establish a prospective protocol
- Identify biomarkers for early diagnosis of pancreatic cancer in this high-risk population
Exocrine Pancreatic Insufficiency
- Determine the effectiveness of pancreatic enzyme replacement therapy and important cofactors necessary for correcting exocrine pancreatic insufficiency
- Investigate the utility of direct pancreatic function testing in chronic pancreatitis.
- Understand regulation of pancreatic digestive function in health and disease mediated by calcium, insulin, nitric oxide and neural signaling.
- Explore dietary approaches to pancreatic regeneration to achieve an adequate supply of pancreatic digestive enzymes
- Clarify mechanisms for pancreatitis associated with cystic fibrosis transmembrane regulator (CFTR) mutations
- Recognize the impact of CFTR genotype on pancreatic digestive function
- Delineate the natural history of pancreatic cysts
- Identify risk factors for malignant pancreatic cysts
- Identify imaging and biomarker predictors for evolution of cystic tumors to cancer
- Develop a clinical decision tool for patients and clinicians
Pancreatic and Ampullary Cancer
Discriminate benign from malignant pancreatic disease using biomarkers and optical imaging
- Predict pancreatic cancer outcomes based on clinical risk factors (smoking, alcohol, diabetes)
- Determine the differential impact of stent type on treatment of malignant biliary obstruction
- Define and test new metabolic drug targets in pancreatic cancer
- Understand how signaling pathways predispose to early steps in pancreatic carcinogenesis (e.g. acinar to duct metaplasia, epithelial to mesenchymal transition)
- Investigate how signaling pathways promote tumor survival, growth and invasion (e.g. involving Usp9x, NRF2 and Hedgehog)
- Determine the accuracy and cost effectiveness of endoscopic ultrasonography for diagnosing pancreatic neuroendocrine tumors.
- Investigate the natural history of asymptomatic sporadic and syndromic pancreatic neuroendocrine tumors
Research Studies (selected publications)
- D'Souza S L, Elmunzer BJ, Scheiman JM: Long-term follow-up of asymptomatic pancreatic neuroendocrine tumors in multiple endocrine neoplasia type I syndrome. J Clin Gastroenterol 2014, 48:458-461
- Wamsteker EJ, Gauger PG, Thompson NW, Scheiman JM: EUS detection of pancreatic endocrine tumors in asymptomatic patients with type 1 multiple endocrine neoplasia. Gastrointest Endosc 2003, 58:531-535.
- Gauger PG, Scheiman JM, Wamsteker EJ, Richards ML, Doherty GM, Thompson NW: Role of endoscopic ultrasonography in screening and treatment of pancreatic endocrine tumours in asymptomatic patients with multiple endocrine neoplasia type 1. Br J Surg 2003, 90:748-754.
- Anderson MA, Carpenter S, Thompson NW, Nostrant TT, Elta GH, Scheiman JM: Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas. Am J Gastroenterol 2000, 95:2271-2277.
- Bansal R, Tierney W, Carpenter S, Thompson N, Scheiman JM: Cost effectiveness of EUS for preoperative localization of pancreatic endocrine tumors. Gastrointest Endosc 1999;49:19-25.
- Bansal R, Kochman ML, Bude R, Nostrant TT, Elta GH, Thompson NW, Scheiman JM: Localization of neuroendocrine tumors utilizing linear-array endoscopic ultrasonography. Gastrointest Endosc 1995;42:76-79
- Thompson NW, Czako PF, Fritts LL, Bude R, Bansal R, Nostrant TT, Scheiman JM: Role of endoscopic ultrasonography in the localization of insulinomas and gastrinomas. Surgery 1994;116:1131-1138.
Publications – PubMed Links
Mahmoud Al-Hawary, MD
Henry Appelman, MD
Charles Burant, MD
John Carethers, MD
William Chey, MD
Clifford Cho, MD
Karen Choi, MD
David Cooke, MD
Howard Crawford, MD
Casey Dauw, MD
Matthew Davenport, MD
John Del Valle, MD
Jeffrey Desmond, MD
Marina Pasca Di Magliano
Matthew DiMagno, MD
Isaac Francis, MD
Tannaz Guivatchian, MD
Robert Hyzy, MD
James Knol, MD
Richard Kwon, MD
Costas Lyssiotis, PhD
Jorge Machicado Rivero, MD, MPH
William Masch, MD
Stacy Menees, MD
Sofia Merajver, MD, PhD
Michael Mulholland, MD, PhD
Lena Napolitano, MD
Hari Nathan, MD
Chung Owyang, MD
Scott Owens, MD
William Roberts, MD
Wael Saad, MD
Vaibhav Sahai, MD
Allison Schulman, MD
Jiaqi Shi, MD, PhD
James Shields, MD
Christopher Sonnenday, MD
Elena Stoffel, MD
Erik Wamsteker, MD
John Wiley, MD
John Williams, MD, PhD
Jennifer Wyckoff, MD
Mark Zalupski, MD